Don’t Count Those Pennies Just Yet: Watson Cited For Claiming Cost Savings From Sodium Ferric Gluconate
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Office of Prescription Drug Promotion objected to economic claims that the product could reduce ESA use in part because they were based on a subset of the approved population.